



**PATIENT**

Gibson Jones

**SPECIES**

Canine

**BREED**

Standard Poodle

**SEX**

Male Neutered

**AGE**

10 years

**WEIGHT**

59.5lbs

**INTERPRETED BY**

Maggie Machen Lamy,  
DVM, DACVIM  
(Cardiology)

**IMAGING PERFORMED BY**

Jacque Pankatz,  
DVM

**HOSPITAL NAME**

Mountain Vista  
Veterinary Hospital

**REFERRING VET**

Dr. Pankatz

**INVOICE**

28812

**DATE**

2/7/23

**PRESENTING CLINICAL SIGNS**

History: Recheck echo.

-Current medications: Pimobendan 7.5mg BID and Enalapril 10mg BID.

-Pertinent previous echo findings (Idexx 1/2021): LVIDd: 6.6, IVSd: 5.7, FS: 22%, LA: 3.76, LA/AO: 1.6. CVD with LV dysfunction, mild LAE. Rule out diet-related dysfunction. Recommend Pimobendan and diet change.

**ECHOCARDIOGRAM FINDINGS**

2D, m-mode, color flow and doppler imaging is available. Mild diffuse thickening of mitral valve leaflets with no prolapse into the left atrial lumen. Mild central mitral regurgitation with mild left atrial dilation. Normal MR velocity. Mild LV dilation in systole and diastole with moderate systolic dysfunction. The tricuspid valve appears normal with trace tricuspid regurgitation. Normal velocity. Normal right atrial and ventricular diameter and morphology indicating no overt evidence of pulmonary arterial hypertension. The pulmonic and aortic valves are normal in morphology and mobility. Normal pulmonic and aortic outflow velocities with laminar flow. No obvious aortic or pulmonic insufficiency. No pericardial or pleural effusion noted. No obvious cardiac masses.

**CARDIAC CHART**

CANINE CARDIAC PARAMETERS	MR VMAX (m/s)	TR VMAX (m/s)	LA/AO (Boon method)	LA/AO (Heart Base; Swe)	FS (%)	EF (%)	EPSS (cm)
NORMAL PARAMETER	4.5-5.5	<2.7	1.3	<1.6	28-40	40-100	<0.6
PATIENT	5.4	2.7	NM	1.3	19	36	0.48
CANINE CARDIAC PARAMETERS	HR (BPM)	AV VMAX (m/s)	PV MAX (m/s)	BODY WEIGHT (kg)	LA 2D short axis Base view (cm)	LVIDd Avg; 2D and m-mode short axis (cm)	LVIDs Avg; 2D and m-mode short axis (cm)
NORMAL PARAMETER	50-100	0.7-1.7	0.7-1.6	BELOW	BELOW	BELOW	BELOW
PATIENT	NM	1.7	1.5	27.0	2.6	5.3	4.3
*Normal chamber parameters expressed as a mean value (SD)				3	1.27 (5.3)	2.46 (2.46)	1.36 (5.5)
<b>BODY WEIGHT DEPENDENT PARAMETERS</b>				5	1.40 (4.5)	2.74 (5.2)	1.60 (4.7)
<i>*Note: All measurements based upon multi-modal images and methods. An average value is reported.</i>				10	1.50 (3.8)	3.27 (3.5)	2.06 (3.1)
				15	1.83 (2.0)	3.71 (2.4)	2.43 (2.1)
				20	2.02 (1.9)	4.14 (2.2)	2.80 (2.0)
				25	2.18 (2.4)	4.48 (2.9)	3.10 (2.5)
				30	2.33 (3.3)	4.83 (3.9)	3.39 (3.4)
				35	2.48 (4.3)	5.17 (5.0)	3.69 (4.5)
				40	2.62 (5.2)	5.48 (6.1)	3.96 (5.4)
				50	2.88 (7.1)	6.07 (8.3)	4.46 (7.4)

**INTERPRETATION OF THE FINDINGS & FURTHER RECOMMENDATIONS**

Chronic degenerative valve persists with moderate LV dysfunction. As was mentioned in the previous report, this may be a primary cardiomyopathy or may simply be a case of secondary dysfunction with chronic degenerative valve disease. Regardless, what is seen here is similar to the previous study with stable moderate LV dysfunction. The LA and LV are both mildly



**PATIENT**

Gibson Jones

improved, likely due to Pimobendan therapy. Assuming the diet was changed, this may also be contributing to a stable overall picture. No obvious additional issues are identified.

**SPECIES**

Canine

Given these findings, reasonable to continue Pimobendan and Enalapril as prescribed. Prognosis remains guarded long-term; however, stability is certainly a good sign. Patient may be at risk to progression to CHF, development of arrhythmias and/or sudden death in the future.

**BREED**

Standard Poodle

Anesthetic risk is considered moderate if needed. Cardiac protective drug choices (opioid/benzodiazepine premedication, propofol or alfaxalone induction, isoflurane gas) are recommended. Pre-oxygenate for 5-10 minutes prior to induction. Monitor for arrhythmias, hypotension, and hypoxia both intra and post-operatively and intervene as necessary. Mild IV fluid restriction is recommended to avoid fluid overload. Avoid heart rate stimulating drugs such as atropine unless clinically indicated.

**SEX**

Male Neutered

**PLAN**

Continue Pimobendan and Enalapril as prescribed. Consider a Taurine supplement 1000mg PO q12h. Baseline BP every 6 months.

**AGE**

10 years

Recommend conservative monitoring with a recheck echocardiogram in 6 months, sooner if any development of clinical signs.


**WEIGHT**

59.5lbs

**IMAGES**

**INTERPRETED BY**

Maggie Machen Lamy,  
DVM, DACVIM  
(Cardiology)



**IMAGING PERFORMED BY**

Jacque Pankatz,  
DVM

The information and recommendations provided are based on the images presented by the referring veterinarian. No evaluation can be communicated regarding pathology that was not visible in the image/video clips provided.

**HOSPITAL NAME**

Mountain Vista  
Veterinary Hospital

Thank you for this referral. This report was generated using transcription software, and minor dictation errors may be present. If the clinical or image interpretation does not parallel your findings or if I can be of any further assistance please contact me.

**REFERRING VET**

Dr. Pankatz

**Maggie Machen Lamy, DVM**  
Diplomate of the American College of Veterinary Internal Medicine (Cardiology)  
info@sonopath.com

**INVOICE**

28812

**DATE**

2/7/23